0QNV.L - Addex Therapeutics Ltd

LSE - LSE Delayed price. Currency in CHF
0.2355
-0.0215 (-8.37%)
At close: 08:37AM BST
Stock chart is not supported by your current browser
Previous close0.2570
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume0
Avg. volumeN/A
Market cap65,411
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.5260
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 18, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (the Company), announced today that it had received written notification from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for the Company’s American Depositary Shares (ADSs) had closed below the minimum US$1.00 per ADS re

  • Globe Newswire

    Addex Reports Q1 2023 Financial Results and Provides Corporate Update

    ADX71149 Phase 2 epilepsy clinical study’s independent interim review committee (“IRC”) recommends continuing study CHF 5.6M ($ 6.1M) of cash and cash equivalents at March 31, 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 11, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported financial results for the first quarter ended March 31, 2023, and

  • Globe Newswire

    Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study

    Cohort 1 progressing through Part 2Cohort 2 recruiting patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study has been recommended to continue by an Independent Interim Review Committee (IRC) following review of unblinded data from

  • Globe Newswire

    Addex Convenes Annual General Meeting 2023

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 5, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its Annual General Meeting will take place on Wednesday May 31, 2023, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual Financial Statements

  • Globe Newswire

    Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023

    Geneva, Switzerland, May 4, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Q1 2023 financial results on Thursday, May 11, 2023. Tim Dyer, CEO and Robert Lütjens, Head of Discovery – Biology, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CES

  • Globe Newswire

    Addex Completes $5.0 Million Equity Financing

    Proceeds to advance allosteric modulator therapeutic pipeline Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 5, 2023 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has completed the equity financing transaction entered into on April 3, 2023 with a leading institutional healthcare investor (the “Investor”), pursuant to which the Comp

  • Globe Newswire

    Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 4, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced data showing that dipraglurant could have beneficial effects on non-motor symptoms (NMS) experienced by Parkinson’s patients in addition to its established positive effects on dyskinesias. Dipraglurant is an mGlu5 negative allosteric modulator (NAM)

  • Globe Newswire

    Addex Raises $5.0 Million in Equity Financing

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 3, 2023 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor (the “Investor”) to sell 7,999,998 shares in the form of 1,333,333 American Depositary Shares (“ADSs”) at a gross purchase price of $0.95 per A

  • Globe Newswire

    Addex Reports Full Year 2022 Financial Results and Provides Corporate Update

    CHF 7.0M ($ 7.4M) of cash and cash equivalents at December 31, 2022ADX71149 Phase 2 study in epilepsy cohort 1 completes part 1 – independent interim review committee (IRC) recommendation expected early Q2 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 30, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported financial results for the full-ye

  • Globe Newswire

    Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023

    Geneva, Switzerland, March 28, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its full-year 2022 financial results on Thursday, March 30, 2023. Tim Dyer, CEO and Robert Lütjens, Head of Discovery – Biology, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media

  • Globe Newswire

    Addex Announces Upcoming Conferences it will participate for H1 2023

    Geneva, Switzerland, March 16, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will participate in the following conferences during the first half of 2023: Bio-Europe Spring: March 20 – 23, 2023; Basel, Switzerland.Swiss Biotech Day: April 24 – 25, 2023; Basel, Switzerland.Bio-Equity Europe: May 14 – 16, 2023; Dublin, Ireland Members of Addex management

  • Globe Newswire

    Addex Regains Nasdaq Listing Compliance

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 9, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement of $1.00 per ADS share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continu

  • Globe Newswire

    Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1

    Data to be reviewed by independent interim review committee (IRC) to keep study blinded Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that enrollment into Part 1 of the Phase 2 clinical study of ADX71149 (JNJ-40411813) for the treatment of epilepsy has been completed. ADX71149 is a selective

  • Globe Newswire

    Addex Provides Corporate Update and Financial Guidance

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 19, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today provided a corporate update, including a review of its pipeline and financial guidance. “We ended 2022 with CHF7.0 million of cash and expect to be able to finance our operations until Q3 2023. We continue to focus on entering into collaborative arra

  • Globe Newswire

    Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration

    Addex to receive USD 1 million in additional research fundingCollaboration continues to advance through drug candidate selection phase Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 8, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the research term of its collaboration agreement with Indivior PLC (LON: INDV) for the discovery of novel o

  • Globe Newswire

    Addex Reports Q3 2022 Financial Results and Provides Corporate Update

    CHF10.4M ($10.4M) of cash and cash equivalents at September 30, 2022Janssen led ADX71149 Phase 2 study in epilepsy on track to complete part 1 in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its Q3 financial results for the period ended September 30, 2022 and provided a corporate upd

  • Globe Newswire

    Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022

    Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its third quarter 2022 financial results on Friday, November 11, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 11:00 EDT / 08:00 PDT) the same day. Title: Addex T

  • Globe Newswire

    Addex Increases Issued Share Capital to Create Treasury Shares

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 1, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (the Company), announced today that it has issued 32,636,476 new registered shares at a nominal value of CHF 0.01 each to Addex Pharma SA, its 100% wholly-owned subsidiary. The new shares, issued from the Company’s authorized capital, are listed on the SIX S

  • Globe Newswire

    Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference

    Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will present at both the Sachs Associates 22nd Annual Biotech in Europe forum in Basel, Switzerland and the Baader Investment Conference in Munich, Germany taking place September 21 - 22, 2022 and September 23, 2022, respectively. In his presentations, Mr. Dyer will pr

  • Globe Newswire

    Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update

    CHF8.8M ($9.3M) of cash and cash equivalents at June 30, 2022CHF4.6M equity financing in July extends cash runway into Q2 2023Janssen led ADX71149 Phase 2 study in epilepsy expected to report data in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its half-year and second quarter financia

  • Globe Newswire

    Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders

    Addex to Receive CHF850,000 ($900,000) of Additional Funding; Addex’s Reserved Indications Expanded to include Chronic Cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its collaboration agreement with Indivior PLC (LON: INDV) for discovering and developing novel oral gamma-aminobutyric

  • Globe Newswire

    Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022

    Geneva, Switzerland, August 12, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2022 financial results on Thursday, August 18, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title: Addex Thera

  • Globe Newswire

    Addex Completes $4.2 Million Equity Financing

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 26, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has completed an equity financing transaction entered into on July 22, 2022 with Armistice Master Fund Ltd. (“Armistice”), a healthcare-focused institutional investor, pursuant to which the Company sold 4,500,000 shares in the form

  • Globe Newswire

    Addex Raises $4.2 million in Equity Financing

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice Master Fund LTV, a healthcare-focused institutional investor, to sell 3,300,000 shares in the form of 550,000 American Depositary Shares (“ADSs”) at a gross purchase price of $1

  • Globe Newswire

    Addex Completes Reduction in Nominal Value of Shares

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the reduction of the nominal value of its issued, authorized and conditional share capital from CHF 1.00 to CHF 0.01, following the expiration of a period of two months after the third creditor call in The Swiss Gazette of Commerce in accordan